...
首页> 外文期刊>The American Journal of Cardiology >Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of Fc gamma RIIa
【24h】

Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of Fc gamma RIIa

机译:临床风险评分的组合评估心血管风险加上FCγ患者的血小板表达

获取原文
获取原文并翻译 | 示例
           

摘要

Platelet expression of Fc gamma RIIa was quantified after myocardial infarction (MI) and we found that patients with high platelet Fc gamma RIIa expression (>11,000/platelet) had a fourfold greater risk of subsequent MI, stroke, and death. This analysis of the original cohort of 197 patients was designed to determine whether platelet expression of Fc gamma RIIa could be used in combination with clinical risk scores (GRACE [Global Registry of Acute Coronary Events] and DAPT [Dual Antiplatelet Therapy]) to refine cardiovascular risk assessment. Platelet expression of Fc gamma RIIa quantified with the use of flow cytometry was broadly distributed in patients stratified into high and low risk groups based on clinical risk scores. In patients identified as high risk by the GRACE score, 62% had high platelet Fc gamma RIIa expression. Similarly, in patients identified as high risk by DAPT, 55% had high platelet Fc gamma RIIa expression. High platelet Fc gamma RIIa expression discriminated high and low risk cohorts in patients with high cardiovascular risk defined by either the GRACE score (high platelet Fc gamma RIIa 18.9% vs low platelet Fc gamma RIIa 0%; odds ratio = 15.7, p = 0.06) or the DAPT score (high platelet Fc gamma RIIa 15.4% vs low platelet Fc gamma RIIa 3.7%; odds ratio = 5.6, p = 0.03) assessment. Platelet expression of Fc gamma RIIa merits additional study to determine whether low platelet Fc gamma RIIa expression can be used to guide early transition to aspirin monotherapy and high platelet Fc gamma RIIa expression can be used to guide continuation of DAPT. (C) 2019 Elsevier Inc. All rights reserved.
机译:在心肌梗死(MI)后量化FcγRIIa的血小板表达,我们发现高血小板FCγγ表达(> 11,000 /血小板)的患者具有较大的后续MI,中风和死亡的风险。这种分析197例患者的原始队列旨在确定FcγRIIA的血小板表达是否可以与临床风险评分组合使用(急性冠状动脉事件的Grace [全球注册表]和DAPT [双抗血小板治疗])来细化心血管风险评估。通过使用流式细胞术量化的Fcγ的Fcγ表达在基于临床风险评分的分层分层为高风险群体的患者中分布。在恩典评分被鉴定为高风险的患者中,62%具有高血小板Fcγriia表达。同样,在鉴定为DAPT的高风险的患者中,55%具有高血小板FCγRIIA表达。高血小板Fcγriia表达在恩典评分定义的高心血管风险患者中歧视高低风险群体(高血小板FcγRIIA18.9%Vs低血小板Fcγ0%;赔率比= 15.7,P = 0.06)或DAPT得分(高血小板FCγRIIA15.4%VS低血小板FCγRIIA3.7%;赔率比= 5.6,P = 0.03)评估。 FcγRIIA的血小板表达优异的额外研究确定低血小板FcγRIIA表达是否可用于引导阿司匹林单药治疗的早期过渡,高血小板FcγRIIA表达可用于引导DAPT的延续。 (c)2019 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号